PD-1 & PD-L1 Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018

PD-1 & PD-L1 Market:

Executive Summary

Adroit Healthcare Services provide the comprehensive list of PD-1 and PD-L1 antibodies that are marketed for different indications and the products that are in development. The main objective of this report is to provide a comprehensive secondary research and market analysis of anti-CD19 antibody pipeline products that are in Phase 3, Phase 2, Phase 1, preclinical and discovery across different indications. This report also provides comprehensive research on the companies that are working on anti-CD19 antibody including the deals and acquisitions.

Report Coverage:

• Clinical (Phase Products)
• Non-clinical (Preclinical and Discovery)
• Dormant and Discontinued
• Technology
• Collaboration details

Companies Mentioned

Bristol-Myers Squibb, Merck & Co., CureTech, AstraZeneca, ImmunOs Therapeutics, Regeneron Pharmaceuticals, Novartis Pharmaceuticals,

Request Sample Report @ https://www.wiseguyreports.com/sample-request/3271726-pd-1-pd-l1-pipeline-analysis-2018

Table of Content:

Executive Summary

Programmed Death 1 (PD-1)

Programmed Death Ligand 1 (PD-L1)

• Description and MOA of PD-1 and PD-L1 pathways
• Significance of PD-1 and PD-L1 inhibitors
• Therapy Areas related to PD-1 and PD-L1
• Biomarkers - PD-1 and PD-L1 inhibitors

Competitive Landscape

• Market Overview
• Marketed Drug Candidate Profiles
• Marketed Drugs Sales
• Details of Patent Expiry of Marketed Drugs

Current and Future Market for PD and PD-L1 inhibitors

Challenges and Barriers associated with use of PD and PD-L1 inhibitors

PD-1/PD-L1 Combinations Profiles

Pipeline Therapeutics

Therapeutics under Development by Companies

Late State Products

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products

• Product Description
• Research and Development
• Product Development Activities

Preclinical & Discovery

• Product Description
• Research and Development
• Product Development Activities

Therapeutic Assessment

• Assessment by Route of Administration
• Assessment by Phase & Route of Administration
• Assessment by Molecule Type
• Assessment by Phase & Molecule type

Collaborations and Acquisitions Details

Dormant Products

Discontinued Products

Appendix

Methodology

Disclaimer

Table 1: Marketed and Pipeline PD-1 and PD-L1 drugs, 2018

Table 2: Sales of Marketed drugs, 2018

Table 3: Patent expiration details – marketed drugs, 2018

Table 4: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2018

Table 5: Products under Development by Companies, 2018

Table 6: Late Stage Products, 2018

Table 7: Mid Stage Products, 2018

Table 8: Early Stage Products, 2018

Table 9: Pre-Clinical and Discovery Products, 2018

Table 10: Assessment by Route of Administration, 2018

Table 11: Assessment by Stage and Route of Administration, 2018

Table 12: Assessment by Molecule Type, 2018

Table 13: Assessment by Stage and Molecule Type, 2018

Table 14: Comparative Analysis

Table 15: Dormant Products

Table 16: Discontinued Products

Figure 1: Marketed and Pipeline PD-1 and PD-L1 drugs, 2018

Figure 2: Sales of Marketed drugs, 2018

Figure 3: Patent expiration details – marketed drugs, 2018

Figure 4: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2018

Figure 5: Products under Development by Companies, 2018

Figure 6: Late Stage Products, 2018

Figure 7: Mid Stage Products, 2018

Figure 8: Early Stage Products, 2018

Figure 9: Pre-Clinical and Discovery Products, 2018

Figure 10: Assessment by Route of Administration, 2018

Figure 11: Assessment by Stage and Route of Administration, 2018

Figure 12: Assessment by Molecule Type, 2018

Figure 13: Assessment by Stage and Molecule Type, 2018

Figure 14: Comparative Analysis

Figure 15: Dormant Products

Figure 16: Discontinued Products

Continuous…

For further information on this report, visit – https://www.wiseguyreports.com/reports/3271726-pd-1-pd-l1-pipeline-analysis-2018

Contact Us:

Norah Trent           

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US); +44 208 133 9349 (UK)